

# Ionis-angptl3-IRx, An Antisense Inhibitor To Angiopoietin-like Protein 3 [angptl3] Reduces Plasma Angptl3 And Lipids In Healthy Volunteers With Elevated Triglycerides

**Purpose:** To evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of Ionis-ANGPTL3 in healthy patients with either normal or elevated triglycerides.

**Trial Design:** Phase 1, randomized, placebo-controlled; N=44; patients were given a single ascending dose (SAD) from 20 - 80 mg or weekly multiple ascending doses (MAD) from 20 - 60 mg subcutaneously for 6 weeks.

**Primary Endpoint:** none

**Secondary Endpoint:** Change in fasting lipids: LDL, HDL, TG, lipoproteins, and lipoprotein lipase activity

Trial Results % mean lipid reduction	LDL-C	HDL-C	Total Cholesterol	Triglycerides	apoC-III	Non-HDL-C
MAD 60 mg doses	35%	25%	36%	66%	68%	40%

**Conclusions:** Ionis-ANGPTL3-IRx lipid reduction was dose-dependent and was found to be safe, well tolerated, and rapidly absorbed.

